RT Journal Article
SR Electronic
T1 Declining SARS-CoV-2 PCR sensitivity with time and dependence on clinical features: consequences for control
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.23.20179408
DO 10.1101/2020.08.23.20179408
A1 Bergmans, B.J.M.
A1 Reusken, C.B.E.M.
A1 van Oudheusden, A.J.G.
A1 Godeke, G.J.
A1 Marinović, A.A. Bonačić
A1 de Vries, E.
A1 Kluiters-de Hingh, Y.C.M.
A1 Vingerhoets, R.
A1 Berrevoets, M.A.H.
A1 Verweij, J.J.
A1 Nieman, A.E.
A1 Reimerink, J.
A1 Murk, J.L.
A1 Swart, A.N.
YR 2020
UL http://medrxiv.org/content/early/2020/08/25/2020.08.23.20179408.abstract
AB Real-time reverse transcription-polymerase chain reaction (RT-PCR) on upper respiratory tract (URT) samples is the primary method to diagnose SARS-CoV-2 infections and guide public health measures, with a supportive role for serology. However, the clinical sensitivity of RT-PCR remains uncertain. In the present study, Bayesian statistical modeling was used to retrospectively determine the sensitivity of RT-PCR using SARS-CoV-2 serology in 644 COVID-19-suspected patients with varying degrees of disease severity and duration. The sensitivity of RTPCR ranged between 79–95%; while increasing with disease severity, it decreased rapidly over time in mild COVID-19 cases. Negative URT RT-PCR results should therefore be interpreted in the context of clinical characteristics, especially with regard to containment of viral transmission based on the ‘test, trace and isolate’ principle.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study has not received funding of any kind.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethics committee METC Brabant, local scientific study authority Wetenschapsbureau ETZAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon request.